OptimizeRx sees 2023 revenue exceeding $68M-$70M, consensus $68.78M

The stronger than expected top-line performance was driven by end of year success with DAAP, as the Company closed the year with 24 deals. This is expected to result in a sequential improvement to the Company’s KPIs. Fourth quarter 2023 adjusted EBITDA is expected to be a new highwater mark for the Company primarily as a result of a higher margin solution mix. During the fourth quarter, the Company successfully completed its previously announced expense reduction measures while streamlining the business and focusing on core strategic priorities. The integration of the Medicx Health acquisition is tracking ahead of internal expectations and the majority of integration activities are expected to be completed by the end of the first quarter of 2024.